Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot (BUVARD76_27)

February 12, 2026 updated by: University Hospital, Rouen
The aim of the study is to screen for hepatitis B, hepatitis C and AIDS viruses using a Dried Blood Spot in drug users

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Avranches, France, 50300
        • Recruiting
        • Caarud Sud Manche
        • Contact:
        • Sub-Investigator:
          • Laure Perrot, Dr
        • Sub-Investigator:
          • Sophie Dubuche, Dr
        • Sub-Investigator:
          • Rado Andriamanéo, Dr
        • Sub-Investigator:
          • Arnaud Verchery, Dr
      • Barentin, France, 76360
        • Recruiting
        • Csapa Barentin
        • Contact:
        • Sub-Investigator:
          • Rémy Truchon, Dr
      • Dieppe, France, 76200
      • Elbeuf, France, 76500
      • Gisors, France, 27140
        • Recruiting
        • Csapa Gisors
        • Sub-Investigator:
          • Rémy Truchon, Dr
        • Contact:
      • Le Havre, France, 76600
        • Recruiting
        • Csapa Nautilia
        • Contact:
        • Sub-Investigator:
          • Quentin Berthon, Dr
      • Pont-Audemer, France, 27504
        • Recruiting
        • Csapa Pont-Audemer
        • Contact:
        • Sub-Investigator:
          • Marie-Claude Flavigny, Dr
      • Rouen, France, 76031
        • Recruiting
        • Chu Rouen
        • Principal Investigator:
          • Ghassan Riachi, Dr
        • Contact:
        • Sub-Investigator:
          • Alexandre Baguet, Dr
        • Sub-Investigator:
          • Jean-Christophe Plantier, Pr
        • Sub-Investigator:
          • Véronique Lemee, Dr
      • Rouen, France, 76000
        • Recruiting
        • Aides Region Normandie
        • Contact:
        • Sub-Investigator:
          • Julien Bord, Dr
        • Sub-Investigator:
          • Stéphane Bord, Dr
      • Rouen, France, 76000
        • Recruiting
        • Csapa-Caarud La Boussole
        • Contact:
        • Sub-Investigator:
          • Véronique Michel, Dr
      • Yvetot, France, 76190
        • Recruiting
        • Csapa Caux Et Bray
        • Contact:
        • Sub-Investigator:
          • Alexandre Hai, Dr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Former or active intravenous and/or nasal drug user
  • Person on opiate substitution therapy

Exclusion Criteria:

  • Person with known active viral infection(s)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Drug user
Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
Diagnostic test: Blood collection using Dried Blood Spot
Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of person with an active hepatitis C infection
Time Frame: Day 1
Day 1
Number of person with an active hepatitis B infection
Time Frame: Day 1
Day 1
Number of person with an active AIDS infection
Time Frame: Day 1
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Rouen

Investigators

  • Principal Investigator: Ghassan RIACHI, MD, University Hospital, Rouen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 2, 2022

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

May 20, 2022

First Submitted That Met QC Criteria

May 20, 2022

First Posted (Actual)

May 25, 2022

Study Record Updates

Last Update Posted (Actual)

February 17, 2026

Last Update Submitted That Met QC Criteria

February 12, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021/0098/HP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatitis B

Clinical Trials on Blood collection using Dried Blood Spot

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe